Cullinan Oncology and Taiho Pharmaceutical Announce Strategic Collaboration to Jointly Develop and Commercialize CLN-081/TAS6417 and Taiho’s Acquisition of Cullinan Pearl
May 12, 2022 02:00 ET
|
Cullinan Oncology, Inc.
Taiho obtains exclusive global rights to CLN-081/TAS6417 outside the U.S.; in the U.S., Taiho and Cullinan Oncology to jointly develop and co-commercialize CLN-081/TAS6417 Cullinan Oncology will...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
May 02, 2022 17:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., May 02, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology to Present Updated Data Highlighting the Therapeutic Potential of CLN-081 in Patients with EGFR Exon 20 Insertion Mutation Positive Non-Small Cell Lung Cancer at the 2022 ASCO Annual Meeting
April 27, 2022 10:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 27, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (Cullinan), a biopharmaceutical company focused on developing a diversified pipeline of targeted therapies...
Cullinan Oncology to Participate in Upcoming Virtual Healthcare Conferences
April 05, 2022 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 05, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 04, 2022 16:34 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., April 04, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”) today announced that the compensation committee of the Company's Board of Directors granted...
Cullinan Oncology Announces Clinical and Regulatory Update for CLN-081 in NSCLC EGFR Exon 20 Patients
March 28, 2022 16:01 ET
|
Cullinan Oncology, Inc.
Confirmed overall response rate improves to 41% at 100mg BID dose level Continued favorable safety and tolerability profile observed in heavily pre-treated patients Pivotal study initiation expected...
Cullinan Oncology Provides Corporate Update and Reports Fourth Quarter and Full Year 2021 Financial Results
March 17, 2022 07:08 ET
|
Cullinan Oncology, Inc.
CLN-081 clinical data support a differentiated clinical profile; regulatory update planned for first quarter 2022 CLN-049 and CLN-619 patient dosing initiated in December 2021 for first-in-human...
Cullinan Oncology to Host CLN-081 Regulatory Update Webinar on March 28, 2022
March 17, 2022 07:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., March 17, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology to Present at the Barclays Global Healthcare Conference
March 09, 2022 08:00 ET
|
Cullinan Oncology, Inc.
CAMBRIDGE, Mass., March 09, 2022 (GLOBE NEWSWIRE) -- Cullinan Oncology, Inc. (Nasdaq: CGEM) (“Cullinan”), a biopharmaceutical company focused on developing a diversified pipeline of targeted...
Cullinan Oncology to Present Data Demonstrating Breadth and Progress of Its Immuno-Oncology Portfolio at AACR 2022
March 08, 2022 17:30 ET
|
Cullinan Oncology, Inc.
Five abstracts selected for poster presentation at the American Association for Cancer Research (AACR) Annual Meeting 2022 Data highlight progress on Cullinan Oncology’s pipeline of therapeutic...